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Background & Objectives: Extended-spectrum β-lactamase (ESBL) producing gram 
negative bacilli are a growing concern in human medicine today. When producing these 
enzymes, organisms (mostly E.coli and K.pneumoniae) become highly efficient at 
inactivating the newer third-generation cephalosporins. The aim of this study was to 
understand the molecular epidemiology of E.coli ESBL producers and to identify the ESBL 
genes carried by them. 
Methods: In this descriptive cross-sectional study, 195 clinical isolates of E.coli collected 
from ICUs was tested. Invitro susceptibility testing, screening for ESBL production and 
minimum inhibitory concentration (MIC) was carried by the disk diffusion methods 
according to the CLSI (Clinical & Laboratory Standard Institute) guideline. All isolates were 
screened for the resistance genes TEM, CTX-M and SHV by a Multiplex PCR assay using 
universal primers. Data were analysed using ANOVA, chi-squre or Fisher exact tests. For all 
tests, p<0.05 was considered significant. 
Results: The occurrence of ESBL-producing strains in the studied population of patients was 
60.51% based on initial screening using the double disk synergy test. The MIC of resistant 
isolates against cephotaxime using the E.test strips was determined: 23.86. The prevalence of 
ESBL-producing strains by PCR assay was 60.51% The presence of the ESBL genes was 
confirmed by DNA sequence analysis. 
Conclusion: These studies are essential for clinicians need to be aware of resistance rates 
observed in clinical isolates. Different prescription policies may influence the rates and 
patterns of resistance. 
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